Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.38 |
| ▸ | PGR | P06401 | 10/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 10/20 | 0.38 |
| ▸ | AR | P10275 | 10/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 7/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7952737 | 0.89 | ADRB3 (0.43) | ADRB3NR3C1PGRNR3C2AR | |
| SCHEMBL1349705 | 0.85 | MRGPRX4 (0.31) | ADRB3 | |
| SCHEMBL12397692 | 0.83 | NR3C1 (0.42) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL12397801 | 0.82 | NR3C1 (0.42) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL7950548 | 0.81 | ADRB3 (0.40) | ADRB3NR3C1PGRNR3C2AR | |
| SCHEMBL1349571 | 0.80 | MRGPRX4 (0.30) | — | |
| SCHEMBL7950082 | 0.80 | NR3C1 (0.42) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL7948516 | 0.80 | NR3C1 (0.45) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL7950611 | 0.79 | NR3C1 (0.40) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL1350041 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183928-A1 | 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183928-A1 | 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-28 | — | — | US | disclosed |
| WO-2009156091-A1 | 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183928-A1 | 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof | HTR3C, HTR3A, ADRB3 | ADRB3 3/4885NR3C1 2099/4885PGR 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.